NitroMed pops on BiDil news

NTMD was up $4.31 (73%) to $10.21 on 14 million shares on Monday after its BiDil showed a significant survival benefit in a U.S. Phase III trial in more than 1,000 African American patients with heart failure. Following a DSMB recommendation, the company halted the double-blind, placebo-controlled A-HeFT trial. All patients will be offered BiDil, which is a combination of hydralazine and isosorbide dinitrate.

NTMD plans to report data from the trial in the fourth quarter. The company plans to amend its previously submitted NDA and hopes to launch BiDil by early 2005. ...